TABLE 4.
Associations of oral corticosteroid use and patient reported outcome measures (PROMs) with the risk of developing new glucocorticoid-toxicities (cumulative worsening score (CWS) ≥1)
| CWS 0 | CWS ≥1 |
Change across CWS 0 and ≥1
Crude OR (95% CI) |
Change across CWS 0 and ≥1
Age- and sex-adjusted OR (95% CI) |
|
| Patients | 38 | 63 | ||
| Glucocorticoid use across CWS 0 and CWS ≥1 | ||||
| Daily prednisolone (mg) V1 | 11.2 (9.0–16.7) | 11.7 (8.1–14.6) | 0.99 (0.95–1.04) | 1.00 (0.95–1.05) |
| Daily prednisolone (mg) V2 | 6.71 (3.83–9.88) | 6.71(3.07–9.06) | 1.00 (0.94–1.06) | 1.00 (0.94–1.06) |
| Receiving maintenance prednisolone V1 | 32 (84.2) | 51 (81.0) | 0.80 (0.27–2.34) | 0.77 (0.26–2.29) |
| Receiving maintenance prednisolone V2 | 20 (52.6) | 32 (50.8) | 0.45 (0.20–1.02) | 0.40 (0.17–0.96) |
| Number of glucocorticoid rescue courses V1 | 5.0 (2.0–6.0) | 5.0 (2.5–7.0) | 1.04 (0.92–1.18) | 1.05 (0.93–1.19) |
| Number of glucocorticoid rescue courses V2 | 1.0 (0.0–2.0) | 2.0 (0–2) | 1.42 (1.03–1.95) | 1.44 (1.04–2.01) |
| Decrease annual prednisolone (mg) (V2–V1) | −1881 (−2806–−1374) | −1760 (−2723–−1393) | 1.01 (0.98–1.05) | 1.01 (0.97–1.05) |
| Percentage decrease annual prednisolone | −42.0 (−62.9–−34.2) | −44.6 (−66.7–−32.2) | 1.01 (0.85–1.20) | 1.01 (0.85–1.29) |
| Baseline glucocorticoid-associated toxicity score | 168 (124–190) | 165 (129–235) | 1.00 (1.00–1.01) | 1.00 (1.00–1.01) |
| Change in PROMs across CWS 0 and CWS ≥1 | ||||
| Mini-AQLQ | 0.77 (0.1–1.5) | 1.0 (−0.1–1.8) | 1.01 (0.75–1.38) | 1.03 (0.75–1.41) |
| SGRQ | −14.0 (−21.0–−5.3) | −11.2 (−20.9–2.9) | 1.01 (0.99–1.03) | 1.01 (0.98–1.03) |
| ACQ5 | −0.6 (−1.8–−0.2) | −0.6 (−1.8–0.0) | 1.04 (0.76–1.43) | 1.02 (0.74–1.41) |
| HADS anxiety | −1.0 (−2.5–1.0) | −1.0 (−3.0–0.5) | 0.97 (0.85–1.10) | 0.96 (0.84–1.09) |
| HADS depression | −1.0 (−3.0–1.0) | −1.0 (−3.0–1.0) | 1.03 (0.91–1.15) | 1.02 (0.90–1.14) |
| EuroQoL-5L5D index | 0.0 (−0.05–0.2) | 0.0 (−0.07–0.1) | 0.44 (0.08–2.32) | 0.51 (0.09–2.77) |
| EuroQoL-5L5D health scale | 7.5 (−5.0–20.0) | 10 (0–20) | 1.01 (0.98–1.03) | 1.01 (0.99–1.04) |
Data are presented as n, median (interquartile range) or n (%), unless otherwise stated. V1: at commencement of mepolizumab; V2: after 12 months treatment; AQLQ: Asthma Quality of Life Questionnaire; SGRQ: St George's Respiratory Questionnaire; ACQ: Asthma Control Questionnaire; HADS: Hospital Anxiety and Depression Scale.